|
1
|
Lenschow DJ, Walunas TL and Bluestone JA:
CD28/B7 system of T cell costimulation. Annu Rev Immunol.
14:233–258. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Teft WA, Kirchhof MG and Madrenas J: A
molecular perspective of ctla-4 function. Annu Rev Immunol.
24:65–97. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Walker LS and Sansom DM: The emerging role
of ctla4 as a cell-extrinsic regulator of T cell responses. Nat Rev
Immunol. 11:852–863. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wakamatsu E, Mathis D and Benoist C:
Convergent and divergent effects of costimulatory molecules in
conventional and regulatory CD4+ T cells. Proc Natl Acad
Sci USA. 110:1023–1028. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Krummel MF and Allison JP: CD28 and ctla-4
have opposing effects on the response of T cells to stimulation. J
Exp Med. 182:459–465. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ichihara F, Kono K, Takahashi A, Kawaida
H, Sugai H and Fujii H: Increased populations of regulatory T cells
in peripheral blood and tumor-infiltrating lymphocytes in patients
with gastric and esophageal cancers. Clin Cancer Res. 9:4404–4408.
2003.PubMed/NCBI
|
|
7
|
Aggarwal S, Sharma SC and N Das S:
Dynamics of regulatory T cells (Tregs) in patients with oral
squamous cell carcinoma. J SurgOncol. 116:1103–1113. 2017.
|
|
8
|
Benevides L, Cardoso CR, Tiezzi DG, Marana
HR, Andrade JM and Silva JS: Enrichment of regulatory T cells in
invasive breast tumor correlates with the upregulation of IL-17A
expression and invasiveness of the tumor. Eur J Immunol.
43:1518–1528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Steeland S, Vandenbroucke RE and Libert C:
Nanobodies as therapeutics: Big opportunities for small antibodies.
Drug Discov Today. 21:1076–1113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wan R, Liu A1, Hou X, Lai Z, Li J, Yang N,
Tan J, Mo F, Hu Z, Yang X, et al: Screening and antitumor effect of
an anti-CTLA-4 nanobody. Oncol Rep. 39:511–518. 2018.PubMed/NCBI
|
|
11
|
Muyldermans S: Nanobodies: Natural
single-domain antibodies. Annual Review of Biochemistry. 775–797.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang M, Liu H, Chen L, Yan M, Ge L, Ge S
and Yu J: A disposable electrochemiluminescence device for
ultrasensitive monitoring of K562 leukemia cells based on aptamers
and simpleZnO@carbon quantum
dots. Biosens Bioelectron. 49:79–85. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu Y, Duan S, He J, Liang W, Su J, Zhu J,
Hu N, Zhao Y and Lu X: Highly sensitive detection of leukemia cells
based on aptamer and quantum dots. Oncol Rep. 36:886–892. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qu K, Wang J, Ren J and Qu X: Carbon dots
prepared by hydrothermal treatment of dopamine as an effective
fluorescent sensing platform for the label-free detection of iron
(III) ions and dopamine. Chemistry. 19:7243–7249. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang ST, Wang X, Wang H, Lu F, Luo PG, Cao
L, Meziani MJ, Liu JH, Liu Y, Chen M, et al: Carbon dots as
nontoxic and high-performance fluorescence imaging agents. J Phys
Chem C Nanomater Interfaces. 113:18110–18114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xing Y and Rao J: Quantum dot
bioconjugates for in vitro diagnostics & in vivo
imaging. Cancer Biomark. 4:307–319. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peter PA, Durflinger KH, Wunderlich JR,
Rosenberg SA and Dudley ME: Enrichment of CD8+ cells from melanoma
tumor-infiltrating lymphocyte cultures reveals tumor reactivity for
use in adoptive cell therapy. J Immunother. 33:547–556. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tran KQ, Zhou J, Durflinger KH, Langhan
MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA and Dudley
ME: Minimally cultured tumor-infiltrating lymphocytes display
optimal characteristics for adoptive cell therapy. J Immunother.
31:742–751. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang L, Wang Z, Lu Z, Xia K, Deng Y, Li
S, Zhang C, Huang Y and He N: Synthesis of LiYF4:Yb, Erupconversion
nanoparticles and its fluorescence properties. J
NanosciNanotechnol. 14:4710–4713. 2014. View Article : Google Scholar
|
|
20
|
Heo NS, Lee SU, Rethinasabapathy M, Lee
EZ, Cho HJ, Oh SY, Choe SR, Kim Y, Hong WG, Krishnan G, et al:
Visible-light-driven dynamic cancer therapy and imaging using
graphitic carbon nitride nanoparticles. Mater Sci Eng C Mater Biol
Appl. 90:531–538. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ji X, Wang H, Song B, Chu B and He Y:
Silicon nanomaterials for biosensing and bioimaging analysis. Front
Chem. 6:382018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lamichhane N, Udayakumar TS, D'Souza WD,
Simone CB II, Raghavan SR, Polf J and Mahmood J: Liposomes:
Clinical applications and potential for image-guided drug delivery.
Molecules. 23:2882018. View Article : Google Scholar
|
|
23
|
Alivisatos P: The use of nanocrystals in
biological detection. Nat Biotechnol. 22:47–52. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baker M: Nanotechnology imaging probes:
Smaller and more stable. Nat Methods. 7:957–962. 2010. View Article : Google Scholar
|
|
25
|
Hamers-Casterman C, Atarhouch T,
Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N and
Hamers R: Naturally occurring antibodies devoid of light chains.
Nature. 363:446–448. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deffar K, Shi H, Li L, Wang X and Zhu X:
Nanobodies-the new concept in antibody engineering. Afr J
Biotechnol. 8:2645–2652. 2009.
|
|
27
|
Hisada H, Tsutsumi H, Ishida H and Hata Y:
High production of llama variable heavy-chain antibody fragment
(VHH) fused to various reader proteins by Aspergillusoryzae.
Appl Microbiol Biotechnol. 97:761–766. 2013. View Article : Google Scholar : PubMed/NCBI
|
